singapor
usa
meet
session
cover
aspect
epidemiolog
diagnosi
molecular
structur
biolog
vaccin
develop
antivir
drug
discoveri
emerg
rna
virus
current
threat
africa
includ
flavivirus
dengu
zika
alphavirus
chikungunya
coronavirus
filovirus
ebola
influenza
virus
crimean
congo
hemorrhag
fever
viru
rift
valley
fever
viru
lassa
viru
other
data
present
recent
flaviviru
andor
chikungunyaviru
outbreak
angola
burkina
faso
mozambiqu
addit
virus
endem
mani
subsaharan
countri
tasw
seri
emerg
virus
uniqu
africa
success
promot
collabor
research
africa
part
world
well
among
african
scientist
report
summar
lectur
held
meet
highlight
advanc
field
mani
emerg
virus
origin
africa
yet
confer
deal
subject
rare
take
place
africa
problem
african
virologist
rare
opportun
attend
confer
emerg
virus
europ
asia
north
america
result
knowledg
occurr
new
virus
africa
limit
unless
major
outbreak
exampl
preval
dengu
viru
denv
infect
african
countri
bare
studi
known
certainti
whether
zika
viru
zikv
infect
pregnant
women
africa
connect
risk
microcephali
child
case
zikv
epidem
central
south
america
furthermor
african
virologist
gener
well
experienc
diagnost
epidemiolog
knowledg
molecular
biolog
emerg
rna
virus
often
lack
order
make
contribut
chang
lack
commun
exchang
knowledg
two
us
rh
esg
decid
set
seri
small
highli
focus
scientif
meet
praia
tofo
inhamban
provinc
mozambiqu
name
tofo
advanc
studi
week
tasw
meet
restrict
particip
order
allow
robust
discuss
familiar
http
receiv
decemb
accept
decemb
atmospher
first
meet
took
place
septemb
devot
ebola
viru
tasw
dealt
arbovirus
present
discuss
document
recent
book
hilgenfeld
vasudevan
collabor
initi
previou
tasw
alreadi
led
joint
public
among
particip
see
eg
et
al
mugab
et
al
report
tasw
took
place
septemb
devot
emerg
reemerg
virus
gener
meet
particip
came
differ
countri
angola
belgium
botswana
burkina
faso
central
african
republ
china
germani
kenya
mozambiqu
nigeria
singapor
south
africa
tanzania
usa
zimbabw
particip
speaker
africa
particip
african
scientist
student
facilit
stipend
program
major
session
confer
focus
viru
famili
present
summar
follow
order
flavirus
particular
denv
zikv
alphavirus
chikungunya
chikv
coronavirus
ebola
viru
ebov
orthomyxovirus
paramyxovirus
emerg
virus
speaker
review
approv
summari
present
molecular
biolog
antivir
neutral
antibodi
chairperson
athanas
badolo
julien
lescar
julien
lescar
nanyang
institut
structur
biolog
nanyang
technolog
univers
singapor
discuss
flaviviru
protein
structur
dynam
evolut
inhibit
el
sahili
lescar
absenc
effici
safe
vaccin
import
flavirus
zikv
investig
antivir
compound
crucial
public
health
larg
multifunct
enzym
two
activ
site
ie
methyltransferas
rnadepend
rna
polymeras
rdrp
site
consid
major
drug
target
antivir
compound
lim
et
al
activ
site
protein
locat
ntermin
ctermin
domain
respect
alloster
regul
two
site
julien
also
present
unpublish
result
structur
fulllength
inhibitor
design
target
npocket
rdrp
zikv
siew
pheng
lim
novarti
institut
tropic
diseas
denka
life
innov
research
pte
ltd
singapor
report
use
compound
librari
screen
target
denv
rnadepend
rna
polymeras
smith
et
al
approach
allow
identif
sever
compound
lowto
highmicromolar
inhibitori
activ
invitro
assay
cellbas
assay
bind
site
enzym
subdomain
reveal
xray
crystallographi
lianpan
dai
chines
academi
scienc
ca
beij
china
present
work
neutral
monoclon
antibodi
mab
target
envelop
e
protein
zikv
major
factor
respons
cell
tropism
via
cell
entri
receptor
bind
follow
membran
fusion
hostcel
endosom
first
determin
crystal
structur
e
zikv
dai
et
al
show
typic
classii
viral
fusion
protein
origin
defin
lescar
et
al
select
mab
target
evolutionaryconserv
fusion
loop
fl
e
structur
function
character
mab
partial
protect
lethal
challeng
zikv
infect
crystal
structur
analyz
follow
human
could
candid
immunotherapi
second
part
talk
lianpan
present
chimpanze
adenovirusbas
candid
vaccin
zikv
xu
et
al
rational
use
chimpanze
adenoviru
take
advantag
low
preexist
immun
carrier
human
popul
contrast
human
adenoviru
adenoviru
type
engin
express
zikv
e
protein
singl
vaccin
elicit
potent
neutral
mab
achiev
steril
immun
mice
xu
et
al
assay
use
nonhuman
primat
model
diseas
plan
use
candid
vaccin
jianxun
qi
ca
key
laboratori
pathogen
microbiolog
immunolog
chines
academi
scienc
beij
china
present
overview
knowledg
structur
biolog
zikv
see
review
group
investig
result
impress
crystal
structur
capsid
protein
shang
et
al
polymeras
methyltransferas
duan
et
al
import
flaviviru
drug
target
lim
et
al
lim
et
al
rapid
determin
structur
support
part
avail
homolog
structur
denv
deposit
protein
data
bank
pdb
wwwrcsborg
variou
investig
year
zikv
outbreak
jinghua
yan
ca
unit
beij
present
extens
studi
zikvspecif
neutral
antibodi
human
origin
interestingli
three
antibodi
isol
singl
patient
also
demonstr
potent
neutral
activ
line
result
report
antibodi
barbaspaeth
et
al
tharakaraman
et
al
timeofaddit
experi
investig
found
three
antibodi
provid
protect
mice
administ
infect
zikv
epitop
recogn
mab
analyz
structur
studi
found
correspond
tertiari
epitop
contribut
noncontigu
segment
sequenc
polypeptid
chain
use
singl
mab
could
prevent
appear
viru
escap
mutant
grow
zikv
cell
cultur
presenc
three
antibodi
overcam
issu
addit
trispecif
mab
construct
present
three
antibodi
bind
site
within
singl
protein
construct
question
rais
audienc
cost
applic
approach
clinic
set
although
agre
strategi
promis
inform
use
help
design
vaccin
provid
map
molecular
level
epitop
bound
broadli
neutral
antibodi
antibodi
elicit
vaccin
candid
compar
pool
antibodi
abil
confer
protect
challeng
viru
susan
weiss
univers
pennsylvania
philadelphia
pa
usa
gave
account
uniqu
mechan
zikv
resist
antivir
effect
oligoadenyl
synthetaseribonucleas
oa
rnase
l
pathway
banerje
et
al
group
demonstr
zikv
activ
antivir
oasrnas
l
pathway
dramat
reduc
zikv
genom
rna
express
increas
viral
genom
express
rnase
l
knockout
ko
cell
compar
wildtyp
wt
suggest
rnase
lmediat
cleavag
zikv
genom
knockout
oa
rnase
l
gene
surprisingli
fail
enhanc
zikv
replic
compar
wt
cell
moreov
observ
modest
signific
decreas
zikv
replic
rnasel
ko
cell
compar
wt
contrast
find
zikv
flaviviru
denv
well
alphaviru
sindbi
replic
significantli
higher
titer
rnasel
ko
cell
compar
wt
cell
demonstr
strong
antivir
function
carri
activ
rnase
l
infect
virus
addit
poli
ic
mediat
activ
rnase
l
prior
zikv
infect
reduc
replic
wt
rnasel
ko
cell
suggest
mechan
zikv
evas
rnase
l
earli
infect
viral
genom
reservoir
like
establish
protect
rnase
l
cleavag
allow
suffici
viral
replic
found
zikv
replic
factori
rf
contain
viral
transcriptionrepl
complex
dsrna
concentr
characterist
perinuclear
local
wt
cell
ko
cell
express
rnase
l
unabl
activ
rnase
l
compar
rnasel
ko
cell
impli
noncatalyt
role
rnase
l
support
zikv
replic
data
consist
previou
report
rnase
l
interact
cytoskeleton
compon
may
perform
nonenzymat
role
infect
malathi
et
al
summari
susan
propos
rnase
l
play
dual
role
zikv
infectionit
canon
antivir
role
degrad
viral
genom
observ
virus
provir
role
current
uniqu
zikv
maintain
optim
viru
replic
factori
avail
reliabl
reproduc
assay
diagnosi
surveil
play
signific
role
emerg
diseas
consequ
task
commerci
supplier
provid
valid
assay
individu
laboratori
develop
inhous
assay
session
claudia
ohst
euroimmun
south
africa
gave
present
serolog
arboviru
diagnost
avail
compani
mani
arbovirus
durat
viremia
rel
short
serolog
assay
detect
specif
igg
igm
respons
therefor
especi
import
laboratori
confirm
infect
euroimmun
provid
broad
rang
serolog
assay
either
base
elisa
immunofluoresc
platform
use
biochip
technolog
present
focus
develop
assay
support
diagnost
recent
outbreak
zikv
south
central
america
elisa
arbovirus
frequent
base
recombin
antigen
may
instanc
implic
serolog
crossreact
case
zikv
reagent
recombin
antigen
produc
euroimmun
elisa
base
result
obtain
five
differ
group
screen
clinic
serum
sampl
patient
variou
flaviviru
infect
specif
antizikv
igg
igm
elisa
rang
borena
et
granger
et
al
huzli
et
al
kadkhoda
et
al
steinhagen
et
al
patient
suspect
zikv
infect
socal
origin
antigen
sin
phenomenon
due
preexist
antibodi
respons
previou
exposur
anoth
flaviviru
igm
respons
second
differ
flaviviru
infect
may
detect
steinhagen
et
al
evid
use
combin
antiiga
igm
test
may
resolv
problem
appli
identifi
recent
infect
steinhagen
et
al
elis
bonnet
divis
virolog
univers
free
state
bloemfontein
south
africa
gave
present
develop
revers
transcript
recombinas
polymeras
assay
rtrpa
detect
flavivirus
south
africa
rtrpa
requir
special
equip
perform
one
temperatur
use
basic
water
bath
heat
block
henc
assay
may
import
applic
lowresourc
set
field
work
briefli
conserv
region
gene
flavivirus
target
determin
applic
assay
primer
probe
initi
design
west
nile
viru
wnv
cultur
wnv
requir
higher
biocontain
avail
facil
rna
transcrib
synthet
gene
transcrib
rna
use
optim
reaction
condit
product
assay
detect
use
later
flow
system
biotin
molecul
conjug
end
probe
use
reaction
specif
facilit
detect
product
use
later
flow
strip
encompass
antibiotin
molecul
sensit
assay
investig
use
tenfold
dilut
transcrib
rna
known
copi
number
minimum
detect
level
copi
rna
concord
result
convent
rtpcr
reaction
addit
specif
assay
determin
test
rna
flavivirus
arbovirus
known
circul
south
africa
import
travel
assay
unabl
detect
rna
sindbi
viru
crimeancongo
haemorrhag
fever
viru
cchfv
yellow
fever
viru
wesselsbron
viru
assay
detect
rna
usutu
viru
howev
expect
due
sequenc
similar
aim
final
develop
multiplex
assay
flavivirus
southern
africa
crossreact
advantag
henc
result
confirm
rtrpa
simpli
perform
one
temperatur
rapid
detect
product
use
later
flow
system
mariam
mirambo
depart
microbiolog
immunolog
weill
bugando
school
medicin
cathol
univers
health
alli
scienc
mwanza
tanzania
present
studi
seroposit
factor
associ
zikv
denv
infect
among
symptomat
pregnant
women
attend
antenat
clinic
rural
urban
area
mwanza
tanzania
denv
zikv
may
endem
african
countri
inform
preval
incid
still
miss
due
absenc
systemat
case
report
african
countri
pregnant
women
attend
antenat
clinic
present
dengu
zika
symptom
enrol
igm
igg
denv
zikv
determin
seroposit
record
includ
coinfect
case
confirm
pcr
domingo
jandondo
instituto
nacion
de
em
ini
maianga
luanda
angola
gave
present
outbreak
dengu
occur
angola
april
june
period
approxim
case
dengu
report
health
author
angola
peak
outbreak
april
molecular
analysi
rtpcr
sequenc
use
wherev
possibl
identifi
serotyp
circul
countri
frequent
identifi
serotyp
dengu
type
identifi
case
one
case
dengu
type
also
identifi
analysi
patient
demograph
suggest
age
group
frequent
infect
year
live
urban
area
male
femal
infect
major
case
report
patient
resid
capit
angola
luanda
outbreak
rais
awar
diseas
countri
effort
made
increas
surveil
antivectori
control
measur
also
implement
athanas
badolo
laboratoir
dentomologi
fondamental
et
ouaga
ouagadoug
burkina
faso
present
result
entomolog
studi
aed
spp
mosquito
popul
around
ouagadoug
capit
burkina
faso
experienc
largest
record
dengu
outbreak
coincid
outbreak
potenti
breed
adult
rest
site
sampl
indoor
outdoor
periurban
urban
district
abund
mosquito
aed
aegypti
individu
exhibit
wide
rang
variat
morpholog
charact
associ
aegypti
formosu
form
speci
subsampl
analyz
identifi
blood
meal
sourc
mutat
affect
insecticid
suscept
result
show
aed
aegypti
highli
anthropophil
endoand
exophil
tendenc
adult
mosquito
resist
pyrethroid
insecticid
adult
larva
suscept
organophosph
result
provid
muchneed
initi
evid
base
essenti
develop
vector
control
strategi
prior
futur
outbreak
aed
aegyptiborn
arbovirus
burkina
faso
give
overview
epidemiolog
pathogenesi
reemerg
chikv
discuss
molecular
mechan
alphaviru
entri
exit
alphavirus
includ
chikv
encephalit
virus
import
human
anim
pathogen
highli
organ
envelop
virus
intern
nucleocapsid
contain
plussens
rna
surround
viral
membran
contain
extern
lattic
transmembran
protein
viru
replic
occur
cytoplasm
envelop
deriv
bud
via
process
mediat
protein
capsid
protein
interact
exclud
host
membran
protein
mani
question
remain
capsid
protein
select
assembl
viral
rna
mechan
viral
bud
brown
et
al
alphavirus
infect
cell
free
viru
particl
transmit
infect
cell
via
intercellular
extens
martinez
kielian
extens
induc
viru
infect
host
cell
express
viral
structur
protein
absenc
infect
process
celltocel
transmiss
requir
bud
fusionact
viral
particl
transfer
neighbor
noninfect
cell
extens
involv
reorgan
actin
microtubul
system
protect
viru
neutral
host
antibodi
st
patrick
reid
patholog
microbiolog
depart
univers
nebraska
omaha
ne
usa
talk
integr
clinic
molecular
data
toward
elucid
mechan
underli
chikvinduc
arthriti
fever
polyarthralgia
polyarthr
main
symptom
patient
infect
chikv
chang
et
al
understand
mechan
involv
symptom
arthriti
help
search
new
therapeut
vaccin
still
avail
model
develop
includ
vascular
bone
model
cocultur
tricultur
cell
model
evalu
interact
involv
chikv
infect
synovi
fluid
person
infect
chikv
also
analyz
protein
associ
arthralgia
identifi
posttransl
modif
includ
citrullin
carbamyl
play
import
role
pathophysiolog
arthriti
establish
leen
delang
rega
institut
medic
research
leuven
belgium
present
overview
antivir
strategi
chikv
caus
acut
arthralgia
evolv
chronic
arthralgia
case
repurpos
antivir
develop
virus
cellbas
screen
new
antivir
chikv
use
exampl
repurpos
favipiravir
develop
antivir
influenza
act
broadli
viral
rnadepend
rna
polymeras
rdrp
favipiravir
produc
strong
inhibit
acut
chikv
replic
cell
cultur
mous
model
act
viral
rdrp
contrast
effect
mous
model
chronic
infect
observ
result
suggest
chronic
condit
either
replic
andor
viral
rna
defect
delang
et
al
cellbas
screen
class
small
molecul
triazolo
one
inhibit
cap
activ
identifi
abdelnabi
et
al
spite
strong
conserv
among
protein
compound
show
surpris
specif
chikv
vs
alphavirus
mutat
caus
resist
compar
studi
mosquito
vs
mammalian
host
emphas
import
evalu
role
vector
drug
resist
viral
fit
mark
helmholtz
centr
infect
research
braunschweig
germani
present
research
strategi
identifi
antivir
lead
compound
use
screen
natur
product
myxobacteri
metabolit
soraphen
sora
found
broadspectrum
antivir
inhibit
acetyl
coenzym
carboxylas
thu
affect
hostcel
lipid
metabol
sora
inhibit
format
membran
web
cellular
structur
gener
serv
platform
replic
rna
virus
studi
show
sora
inhibit
replic
hepat
c
viru
hcv
human
immunodefici
viru
hiv
denv
koutsoudaki
et
al
fletasoriano
et
al
second
natur
product
shown
broad
antivir
activ
lantibiot
peptid
labyrinthopeptin
et
al
molecul
display
broad
antivir
activ
envelop
virus
includ
flavivirus
chikv
interact
phosphatidyl
ethanolamin
viral
membran
lead
perfor
virucid
effect
contrast
cell
rel
resist
presum
due
decreas
access
pe
cell
vs
viral
membran
well
abil
cell
carri
membran
repair
interest
defin
mechan
two
antivir
compound
explor
abil
act
antivir
vivo
santo
instituto
nacion
de
maputo
mozambiqu
report
evalu
serum
sampl
patient
acut
fever
mozambiqu
increas
malaria
case
report
mozambiqu
case
acut
fever
treat
antimalari
antibiot
frequent
without
consid
possibl
alphaviru
viral
infect
studi
serum
sampl
reveal
presenc
igm
igg
antibodi
zikv
wnv
chikv
high
proport
coinfect
arbovirus
malaria
also
observ
result
strongli
support
import
expand
diagnost
capabl
better
identifi
caus
improv
manag
acut
fever
eduardo
samo
gudo
instituto
nacion
de
maputo
mozambiqu
present
ongo
effort
mozambiqu
build
diseas
detect
emerg
respons
core
capac
emerg
virus
recent
report
occurr
dengu
outbreak
countri
massangai
et
al
retrospect
investig
larg
serum
bank
store
nation
institut
health
show
arbovirus
circul
unsuspect
sever
year
mozambiqu
histor
data
demonstr
arbovirus
found
mozambican
sinc
gudo
et
al
gudo
et
al
surveil
system
establish
monitor
occurr
arbovirus
emerg
virus
well
build
capac
earli
detect
emerg
pathogen
data
establish
surveil
emerg
virus
found
case
dengu
chikungunya
rift
valley
fever
hantaviru
crimeancongo
hemorrhag
fever
across
differ
sentinel
site
chau
et
al
mugab
et
al
muianga
et
al
oludel
et
al
result
driven
establish
diagnost
capac
earli
detect
rapid
respons
emerg
virus
mozambiqu
serolog
assay
establish
establish
molecular
neutral
assay
underway
nation
institut
health
rapid
respons
team
train
arbovirus
emerg
virus
nation
institut
health
susan
r
weiss
dept
microbiolog
univers
pennsylvania
philadelphia
pa
usa
open
session
give
overview
coronaviru
pathogenesi
replic
hostcel
respons
infect
report
coronaviru
phosphodiesteras
antagon
innat
immun
respons
host
laboratori
focus
antivir
synthetas
ribonucleas
l
oasrnas
l
pathway
rnase
l
activ
doublestrand
ds
rna
cleav
host
viral
singlestrand
rna
thu
downregul
protein
synthesi
viral
replic
group
demonstr
accessori
protein
mous
hepat
viru
mhv
well
lineag
betacoronavirus
cytoplasm
protein
display
phosphodiesteras
pde
activ
prevent
rnase
l
activ
zhao
et
al
goldstein
et
al
mhv
celltyp
organspecif
virul
factor
requir
replic
liver
induct
hepat
interestingli
replic
brain
enceph
accessori
protein
encod
merscov
lineag
c
betacoronavirus
identifi
homologu
mhv
also
antagon
oasrnas
l
antivir
pathway
thornbrough
et
al
contrast
mainli
local
nucleu
suggest
enzymat
role
compart
support
find
merscov
mutant
virus
express
either
catalyt
inact
express
cytoplasm
display
similar
phenotyp
regard
replic
upregul
interferonlambda
interferonstimul
gene
express
addit
data
point
catalyt
role
nucleu
final
rnase
l
activ
lead
apoptosi
infect
cell
suggest
antivir
activ
due
elimin
infect
cell
well
viral
genom
rna
degrad
yi
shi
ca
key
laboratori
pathogen
microbiolog
immunolog
univers
chines
academi
scienc
beij
address
entri
mechan
merscov
sarscov
trimer
spike
glycoprotein
whose
overal
structur
remain
investig
group
set
solv
structur
protein
order
elicit
function
design
broadlyneutr
antibodi
vaccin
use
cryoelectron
microscopi
high
resolut
threedimension
ectodomain
structur
prefus
complex
obtain
yuan
et
al
except
inher
flexibl
receptor
bind
domain
rbd
resembl
structur
mhv
protein
fusion
peptid
identifi
potenti
target
broadli
neutral
antibodi
susan
daniel
rf
smith
school
chemic
biomolecular
engin
cornel
univers
ithaca
ny
usa
discuss
influenc
calcium
ion
insert
fusion
peptid
hostcel
membran
lipid
order
entri
process
coronaand
ebola
virus
current
knowledg
relat
conform
chang
spike
protein
exposur
fusion
peptid
low
endosom
ph
allow
virus
enter
cytosol
howev
becom
clear
increas
calcium
concentr
within
endosom
also
correl
infect
virus
susan
describ
calcium
stabil
structur
fusion
peptid
conform
chang
spike
promot
insert
hostcel
membran
furthermor
data
show
calcium
concentr
increas
lipid
order
increas
well
membran
fusion
activ
higher
fusogen
activ
link
higher
infect
rate
observ
presenc
higher
calcium
level
tiffani
tang
rf
smith
school
chemic
biomolecular
engin
cornel
univers
ithaca
ny
usa
present
studi
antifusogen
monoclon
antibodi
direct
coronavirus
fusion
peptid
spike
protein
coronavirus
expos
proteas
cleavag
enabl
direct
fusion
plasma
membran
surfac
endosom
recent
cryoem
studi
demonstr
expos
prefus
region
coronavir
fusion
peptid
fp
elicit
broadli
neutral
antibodi
wall
et
al
sarscov
spike
protein
encompass
twoheptad
repeat
prefus
fp
region
use
gener
monoclon
antibodi
mice
function
character
reveal
antibodi
present
virushost
cell
membran
fusion
order
block
infect
sarscov
pseudoparticl
due
conserv
fusion
peptid
crossprotect
merscov
pseudoparticl
also
demonstr
albrecht
von
brunn
max
von
pettenkof
institut
ludwigmaximiliansunivers
munich
germani
colleagu
use
yeast
twohybrid
system
identifi
interact
partner
two
sarscov
domain
uniqu
domain
sud
papainlik
proteas
pl
pro
interact
valid
method
includ
mass
spectrometri
splityfp
assay
gel
filtrat
sud
pl
pro
embed
lei
et
al
interact
stabil
ubiquitin
ligas
ringfing
chi
zincfing
domaincontain
ubiquitin
therebi
lead
degrad
malauer
et
al
thu
cov
protein
contain
sudpl
pro
counteract
host
defens
two
distinct
manner
lead
degrad
stabil
previous
report
direct
deisgyl
activ
pl
pro
interfer
cellular
isgyl
lindner
et
al
anoth
bind
partner
sarscov
sud
poli
bind
proteininteract
protein
involv
initi
translat
ntermin
residu
ntermin
subdomain
sud
also
name
macrodomain
bind
middl
domain
sud
poli
bind
protein
pabp
form
ternari
complex
stimul
translat
stimul
translat
combin
cov
degrad
specif
host
viral
mrna
could
lead
preferenti
synthesi
viral
protein
maria
esk
institut
biochemistri
univers
germani
colleagu
investig
unknown
domain
ud
within
hcov
alphacoronaviru
found
presenc
ud
effect
peptidolyt
activ
ctermin
neighbor
within
papainlik
proteas
domain
possibl
similar
middl
domain
sud
also
term
macrodomain
encod
part
betacoronaviru
sarscov
domain
bind
gquadruplex
rna
process
appar
requir
rna
synthesi
tan
et
al
kusov
et
al
studi
way
ud
explor
similar
differ
alpha
beta
coronaviru
macrodomain
rolf
hilgenfeld
institut
biochemistri
univers
germani
colleagu
aim
design
broadspectrum
antivir
alphaand
betacov
enterovirus
rational
approach
virul
human
cov
infect
rel
small
number
peopl
drug
inhibit
enterovirus
well
cov
commerci
viabl
larg
number
enteroviru
infect
approach
possibl
due
similar
substratebind
site
enteroviru
cov
main
proteas
hilgenfeld
rolf
colleagu
employ
structurebas
design
peptidomimet
alphaketoamid
test
inhibitor
proteas
coxsackieviru
enteroviru
well
main
proteas
sarscov
differ
pocket
among
four
enzym
present
challeng
design
common
inhibitor
thu
far
best
inhibitor
cyclopentylmethyl
cyclohexylmethyl
moieti
display
lowor
submicromolar
ec
valu
three
type
virus
cell
cultur
compound
highest
report
antivir
activ
betacoronaviru
merscov
cell
optim
pharmacokinet
properti
session
ebov
offer
insight
sever
aspect
relat
virus
petru
jansen
van
vuren
centr
emerg
zoonot
parasit
diseas
nation
institut
communic
diseas
johannesburg
south
africa
present
analysi
spread
ebov
sierra
leon
group
sequenc
genom
confirm
ebola
viru
diseas
evd
case
major
western
region
countri
extens
phylogenet
analysi
allow
identif
certain
area
either
sourc
sink
viru
capit
freetown
play
special
role
outbreak
sublineag
predomin
makona
ebov
lineag
present
probabl
due
patient
move
freetown
part
countri
hope
receiv
better
treatment
result
freetown
play
substanti
role
maintain
perpetu
outbreak
sierra
leon
christel
bobossi
gadia
virolog
depart
institut
pasteur
bangui
central
african
republ
present
retrospect
epidemiolog
studi
filoviru
monkey
poxviru
arboviru
preval
human
popul
live
tropic
forest
central
african
republ
antibodi
track
year
clearli
show
year
spike
case
preval
certain
viru
strain
high
preval
ebov
igg
found
pygmi
seem
higher
seropreval
ebolazair
viru
nonpygmi
differ
explain
geograph
factor
closer
proxim
democrat
republ
congo
republ
congo
david
nkwe
depart
biolog
scienc
biotechnolog
botswana
intern
univers
scienc
technolog
palapy
botswana
present
inspir
propos
conduct
metagenom
analysi
bat
virom
botswana
present
data
region
lack
spite
strong
preval
bat
reservoir
mani
zoonot
virus
goal
studi
would
assess
preval
zoonot
virus
bat
possibl
discov
new
virus
studi
bat
human
interact
consequ
disturb
bat
habitat
human
activ
present
follow
interest
discuss
method
collect
sampl
bat
final
present
session
sina
bavari
us
armi
medic
research
institut
infecti
diseas
usamriid
frederick
md
usa
present
overview
methodolog
success
antivir
drug
discoveri
develop
point
antivir
drug
safe
inexpens
easili
access
wide
avail
easi
store
administ
long
shelflif
offer
clear
uncompl
pathway
regulatori
approv
ideal
drug
broadli
target
sever
viru
famili
act
stage
infect
well
distribut
affect
organ
sina
went
discuss
advantag
disadvantag
target
host
protein
versu
viral
protein
former
target
may
offer
larger
potenti
yield
broadspectrum
antivir
may
reduc
problem
resist
develop
viru
compound
may
alreadi
avail
need
repurpos
potenti
disadvantag
antivir
target
host
protein
includ
toxic
collater
effect
due
differ
distribut
target
locat
infect
lack
complet
understand
target
biolog
difficulti
develop
assay
establish
pharmacokineticspharmacodynam
pkpd
relationship
often
unclear
riski
regulatori
pathway
opposit
true
directact
antivir
less
prone
exhibit
toxic
base
target
gener
easier
build
assay
establish
pkpd
regulatori
pathway
usual
clearer
may
lead
develop
viral
resist
depend
structur
may
limit
scope
term
address
viru
famili
sina
discuss
differ
stage
viral
life
cycl
target
distribut
viru
differ
organ
cell
type
well
impact
therapeut
exampl
ebov
question
whether
direct
act
antivir
synthet
small
molecul
biolog
monoclon
antibodi
interferon
present
discoveri
screen
pipelin
establish
usamriid
describ
success
nucleotid
analogu
remdesivir
evalu
collabor
institut
cdc
compound
develop
gilead
scienc
phosphoramid
prodrug
pyrrolo
adenin
cnucleosid
display
ec
valu
nm
variou
filovirus
differ
cell
includ
human
macrophag
also
activ
arenavirus
coronavirus
agostini
et
al
cc
final
stage
massiv
evd
epidem
west
africa
compound
succes
use
treat
evd
newborn
child
et
al
relaps
survivor
jacob
et
al
almiro
tivan
instituto
nacion
de
ministri
health
maputo
mozambiqu
provid
overview
genet
character
mozambican
influenza
virus
occupi
ecolog
nich
southern
africa
tivan
et
al
analyz
antigen
profil
hemagglutinin
ha
sequenc
inform
suscept
neuraminidas
na
inhibitor
found
subtyp
virus
remain
close
relat
antigen
genet
vaccin
viru
wide
distribut
virus
belong
genet
group
addit
also
studi
influenza
virus
mozambiqu
major
antigen
similar
vaccin
viru
ahong
ha
na
sequenc
belong
subclad
close
relat
virus
circul
southern
africa
influenza
b
virus
also
antigen
similar
season
vaccin
viru
overal
mozambican
influenza
b
virus
close
relat
southern
african
virus
sensit
oseltamivir
zanamivir
find
suggest
region
circul
virus
highlight
need
continu
epidemiolog
surveil
detect
monitor
emerg
influenza
virus
iolanda
monjan
agrarian
research
institut
mozambiqu
maputo
mozambiqu
introduc
audienc
situat
poultri
product
system
mozambiqu
major
poultri
product
homebas
lack
rigor
biosecur
guidelin
pose
risk
transmiss
avian
influenza
virus
human
group
collect
total
sera
backyard
poultri
found
sera
posit
avian
influenza
type
virus
posit
sera
test
subtyp
virus
neg
highlypathogen
outbreak
confirm
bird
southern
african
develop
commun
sadc
countri
includ
drc
zimbabw
south
africa
veterinari
author
mozambiqu
decid
suspend
import
movement
poultri
poultri
product
affect
region
also
introduc
intens
clinic
examin
surveil
larger
poultri
industri
target
farm
import
dayold
bird
hatch
egg
infect
countri
prior
outbreak
clinic
symptom
report
total
swab
sampl
test
qrtpcr
viru
neg
also
establish
new
qrtpcr
protocol
detect
gene
aim
passiv
activ
avian
influenza
surveil
date
total
sampl
test
none
posit
hao
song
beij
institut
life
scienc
institut
microbiolog
chines
academi
scienc
beij
china
present
studi
subtyp
virus
wide
circul
domest
poultri
china
colleagu
evalu
receptorbind
properti
two
repres
isol
avian
ha
contain
swine
ha
contain
found
avian
isol
preferenti
bind
avian
receptor
swine
isol
preferenti
bind
human
receptor
obvious
prerequisit
transmiss
human
confirm
aminoacid
substitut
pivot
shift
receptor
bind
result
human
receptorbind
featur
similar
pandem
impli
swine
virus
potenti
caus
human
infect
group
also
reveal
structur
basi
receptorbind
chang
therebi
enhanc
understand
shift
receptor
bind
atom
level
find
suggest
enhanc
surveil
virus
pay
attent
evolut
rachel
fearn
boston
univers
school
medicin
boston
usa
present
studi
initi
transcript
replic
differ
famili
nonseg
negativestrand
rna
virus
noton
fearn
group
show
respiratori
syncyti
viru
rsv
differ
initi
site
genom
replic
posit
transcript
posit
cressey
et
al
use
invitro
rna
synthesi
assay
show
initi
posit
occur
independ
polymeras
prefer
initi
initi
site
select
could
modul
rel
concentr
atp
versu
gtp
also
show
polymeras
human
metapneumoviru
anoth
pneumoviru
also
initi
posit
promot
contrast
polymeras
paramyxovirus
human
parainfluenza
viru
nipah
viru
niv
initi
posit
promot
ebov
polymeras
initi
posit
promot
find
suggest
differ
nonseg
negativestrand
rna
virus
evolv
differ
initi
mechan
session
cover
rang
topic
diagnost
epidemiolog
molecular
virolog
varieti
emerg
virus
diagnost
side
felic
burt
nation
health
laboratori
servic
univers
free
state
bloemfontein
south
africa
present
data
develop
elisabas
assay
allow
detect
antibodi
cchfv
patient
sera
approach
would
circumv
need
cultur
highli
pathogen
viru
diagnost
purpos
surveil
studi
approach
comput
predict
follow
function
analysi
use
identifi
immunolog
epitop
within
np
g
protein
goedhal
et
al
peptid
contain
region
util
basi
elisa
assay
trial
indic
cchfv
antibodi
could
detect
major
survivor
test
valid
approach
epidemiolog
side
inocencio
chongo
instituto
nacion
de
maputo
mozambiqu
present
result
studi
zoonot
infect
mozambiqu
research
signific
much
popul
mozambiqu
directli
involv
agricultur
close
contact
anim
examin
preval
zoonot
infect
serum
sampl
febril
patient
test
antibodi
brucella
hantaviru
cchfv
igm
igg
antibodi
three
pathogen
could
detect
hantaviru
highest
preval
rate
evid
coinfect
case
data
show
pathogen
circul
mozambiqu
consid
possibl
caus
agent
patient
present
febril
ill
anoth
epidemiolog
studi
zoonot
infect
belisario
moian
eduardo
mondlan
univers
maputo
mozambiqu
report
result
studi
rift
valley
fever
rvf
phleboviru
seropreval
cattl
goat
sheep
african
buffalo
provinc
mozambiqu
moian
et
al
overal
seropreval
found
highest
frequenc
found
cattl
african
buffalo
southern
central
provinc
outbreak
rvf
symptom
report
herd
time
period
asid
small
outbreak
south
belisario
suggest
rvf
phleboviru
silent
circul
mozambiqu
third
epidemiolog
studi
present
asab
dzikwi
univers
jo
nigeria
set
explor
factor
affect
rabi
viru
dissemin
nigeria
rabi
viru
endem
dog
nigeria
slaughter
dog
test
posit
viru
sequenc
analysi
viru
suggest
crossbord
transport
viru
neighbor
countri
cameroon
chad
dog
trade
practic
thought
respons
research
perform
examin
role
dawacki
dog
market
larg
dog
market
nigeria
averag
dog
sold
market
day
questionnair
reveal
dog
sourc
northern
part
nigeria
neighbor
niger
chad
cameroon
sold
buyer
southern
provinc
nigeria
thu
research
reveal
dog
market
conduit
import
foreign
strain
rabi
viru
nigeria
togeth
three
epidemiolog
studi
reveal
preval
differ
emerg
pathogen
mean
dissemin
provid
valuabl
fact
inform
surveil
control
measur
molecular
virolog
perspect
thoma
strecker
marburg
germani
present
research
compar
refer
strain
lassa
viru
josiah
viru
new
strain
lassa
viru
link
togo
shown
comparison
josiah
strain
z
protein
togo
strain
bud
effici
cell
express
alon
despit
presenc
late
domain
motif
bud
activ
togo
strain
z
protein
could
enhanc
coexpress
nucleoprotein
np
wherea
np
effect
josiah
viru
bud
find
show
differ
strain
lassa
viru
evolv
differ
bud
mechan
vari
depend
np
result
implic
antivir
drug
design
emphas
need
includ
relev
viru
strain
molecular
biolog
studi
report
tasw
reveal
dengu
andor
chikungunya
outbreak
occur
sever
african
countri
eg
angola
burkina
faso
mozambiqu
recent
year
dengu
probabl
endem
mani
region
subsaharan
africa
diseas
often
misdiagnos
malaria
patient
show
low
level
plasmodium
parasitemia
even
though
caus
acut
diseas
addit
denv
evid
zikv
chikv
rvfv
hantavirus
lassa
viru
cchfv
endem
sever
african
countri
rabi
virus
endem
dog
nigeria
mani
african
countri
influenza
virus
appear
occupi
ecolog
nich
mozambiqu
interest
also
high
preval
antibodi
ebola
marburg
virus
human
live
tropic
forest
central
african
republ
among
human
coronavirus
hcov
common
agent
acut
respiratori
infect
eg
nigeria
kolawol
et
al
furthermor
merscov
widespread
camel
arabian
peninsula
also
throughout
west
east
africa
chu
et
al
gikonyo
et
al
even
though
genom
merscov
strain
display
region
differ
may
affect
zoonot
potenti
chu
et
al
omnipres
distribut
viru
camel
certainli
constitut
continu
threat
meet
also
provid
illumin
survey
critic
insect
vector
challeng
surveil
control
present
highlight
need
continu
extens
surveil
studi
confirm
geograph
distribut
circul
emerg
reemerg
virus
africa
outbreak
occur
potenti
occur
molecular
virolog
studi
present
intern
expert
constitut
major
highlight
includ
structur
function
studi
denv
zikv
nonstructur
protein
capsid
influenza
viru
hemagglutinin
lassa
viru
z
protein
rna
polymeras
nonseg
negativestrand
rna
virus
betacoronaviru
well
coronavirushost
interact
coronavirushostcel
membran
fusion
antifusogen
antibodi
interest
comparison
viral
mechan
counteract
typei
interferon
product
infect
cell
rnase
l
pathway
show
coronavirus
denv
sindbi
viru
zikv
display
differ
interfer
rnase
l
activ
extens
studi
zikvspecif
neutral
antibodi
human
origin
present
interact
mab
zikv
e
protein
character
structur
biolog
studi
essenti
vaccin
design
alreadi
led
develop
zikv
vaccin
base
recombin
adenoviru
express
zikv
e
protein
mani
new
antivir
compound
also
present
meet
includ
hit
librari
screen
protein
denv
phosphoamid
nucleosid
prodrug
remdesivir
activ
ebov
arenavirus
coronavirus
favipiravir
triazolo
one
inhibit
respect
rna
polymeras
cap
activ
chikv
alphaketoamid
target
main
proteas
coronavirus
proteas
enterovirus
natur
product
soraphen
labyrinthopeptin
broadspectrum
antivir
studi
molecular
mechan
virus
discuss
meet
continu
provid
therapeut
strategi
antivir
target
summari
tasw
provid
import
inform
emerg
reemerg
virus
africa
countermeasur
taken
well
investig
molecular
biolog
rna
virus
discoveri
antivir
drug
sever
new
collabor
initi
virologist
africa
one
hand
asia
europ
usa
also
among
african
scientist
particip
felt
mix
particip
breadth
research
aspect
emerg
virus
made
attend
tasw
uniqu
valuabl
experi
